21 Aug 2020 --- Conagen has created a proprietary process for the scalable production of a non-GMO human milk oligosaccharide (HMO). By harnessing the technology of bioconversion while bypassing genetically modified microbes, the US-based biotechnology firm can create 2’-fucosyllactose (2’FL), which is the most abundant HMO in human milk. Conagen says that as nearly all other HMOs on the market are produced by GMOs, this alternative will appeal to source-sensitive consumers.
